Promarc Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-12-2024
- Paid Up Capital ₹ 0.10 M
as on 23-12-2024
- Company Age 3 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
About Promarc Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mayuresh Katyayan and Girish Kalamkar serve as directors at the Company.
- CIN/LLPIN
U24239MH2021PTC361396
- Company No.
361396
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jun 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Promarc Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mayuresh Katyayan  | Director | 01-Jun-2021 | Current |
| Girish Kalamkar | Director | 01-Jun-2021 | Current |
Financial Performance of Promarc Pharmaceuticals.
Enhance accessibility to Promarc Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Promarc Pharmaceuticals?
Unlock access to Promarc Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Presinus Pharmaceuticals Private LimitedActive 8 years 5 monthsMayuresh Katyayan and Girish Kalamkar are mutual person
Promarc Medicose Private LimitedActive 3 years 4 monthsMayuresh Katyayan and Girish Kalamkar are mutual person
- Promarc Sports And Fitness Private LimitedActive 6 years 2 months
Mayuresh Katyayan is a mutual person
- Promarc Hospitals Private LimitedActive 4 years 5 months
Mayuresh Katyayan and Girish Kalamkar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Promarc Pharmaceuticals?
Promarc Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Promarc Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Promarc Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.